Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Susanne Arnold
With
Kentucky Lung Cancer Research Program
Subjects enrolled in the study will be placed in one of two treatment arms. All subjects have a 50-50 chance of being placed into either treatment arm. Treatment Arm 1 will receive chemotherapy alone, Treatment Arm 2 will receive chemotherapy with dexamethasone given pre-treatment.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Untreated, stage IIIB with pleural effusion
Untreated, Stage IV, non-small cell lung cancer
Recurrent after surgery if no previous radiation therapy or chemotherapy were administered as part of their primary treatment, except for palliative radiotherapy
18 years of age or older
ECOG PS 0, 1 or 2
At Least one target lesion according to the RECIST Criteria
Adequate organ and marrow function
You may not be if
Previous cancer history unless they have had curative treatment completed at least 5 years prior to entry.
No previous radiotherapy, chemotherapy or immunotherapy for NSCLC, except for radiation therapy to the brain to control metastasis, bone to control pain, or lung to relieve bronchial obstruction.
No radiation therapy for any previous cancer to more than 25% of bone marrow.
Uncontrolled, intercurrent illness
Non-study corticosteroids
Pregnant women
Peripheral neuropathy greater than grade 1
Uncontrolled seizures, central nervous system disorders
Major surgery within 4 weeks of the start of study treatment
Lack of complete recovery from major surgery.
Glaucoma
Lack of physical integrity of upper gastrointestinal tract, inability to swallow tablets
Severe acquired or hereditary immunodeficiency
Patients with brain metastases must receive definitive treatment (radiation, surgery or both) and be clinically and radiologically stable for 4 weeks \& off corticosteroids for at least 2 weeks prior to randomization.
Clareo Health | Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer
